Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid Academic Article uri icon

Overview

MeSH Major

  • Bone Density Conservation Agents
  • Bone Neoplasms
  • Diphosphonates
  • Imidazoles
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant

abstract

  • PSA is an important prognostic tool for survival in patients with bone metastases from CRPC, and these analyses show that PSA is also prognostic for BDP and SREs regardless of bone-targeted therapy.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2012.05.007

PubMed ID

  • 22633317

Additional Document Info

start page

  • 146

end page

  • 53

volume

  • 65

number

  • 1